Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment
New England Journal of Medicine · 01.10.2026 · 395 (13) · 1299-1309
DOI: 10.1056/nejmoa2607973 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 01.10.2026. Verfasst von Jürgen K Rockstroh und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Anti-HIV Agents, Deoxyadenosines, HIV Infections, HIV-1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Gilead Sciences, Merck Sharp and Dohme.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine I, University Hospital Bonn, Bonn, Germany.
- Midway Immunology and Research Center, Fort Pierce, FL.
- Department of Infectious Diseases, Vall d'Hebron University Hospital, Barcelona.
- Spectrum Health, Vancouver, BC, Canada.
- Department of Medicine, Emory University, Atlanta.
- Hôpital Sainte-Marguerite, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
ORCID-Profile: Chien-Ching Hung, Chloe Orkin
Förderung
- Gilead Sciences
- Merck Sharp and Dohme
Zitieren
APA
Rockstroh, J. K., Ramgopal, M. N., Curran Fàbregas, A., Hedgcock, M., Workowski, K. A., Ronot-Bregigeon, S., Cassetti, I., Brinson, C., Gupta, S. K., Hung, C. C., O'Reilly, M., Slim, J., Gatanaga, H., Shalit, P., Liu, S. Y., Klopfer, S. O., Shihadeh, F., Patel, N., Mercier, R. C., …, & ISLEND-1 Study Team (2026). Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment. New England Journal of Medicine, 395(13), 1299-1309. https://doi.org/10.1056/nejmoa2607973
Vancouver
Rockstroh JK, Ramgopal MN, Curran Fàbregas A, Hedgcock M, Workowski KA, Ronot-Bregigeon S, et al. Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment. New England Journal of Medicine. 2026;395(13):1299-1309. doi:10.1056/nejmoa2607973
BibTeX
@article{Rockstroh2026,
author = {Rockstroh, Jürgen K and Ramgopal, Moti N and Curran Fàbregas, Adrian and Hedgcock, Malcolm and Workowski, Kimberly A and Ronot-Bregigeon, Sylvie and Cassetti, Isabel and Brinson, Cynthia and Gupta, Samir K and Hung, Chien-Ching and O'Reilly, Mark and Slim, Jihad and Gatanaga, Hiroyuki and Shalit, Peter and Liu, Shan-Yu and Klopfer, Stephanie O and Shihadeh, Fadi and Patel, Nidhi and Mercier, Reneé-Claude and Shaughnessy, Melissa and Dvory-Sobol, Hadas and SenGupta, Devi and Llamoso, Cyril and Rhee, Martin S and Orkin, Chloe and ISLEND-1 Study Team, ISLEND-1 Study Team},
title = {Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {13},
pages = {1299--1309},
doi = {10.1056/nejmoa2607973}
}
EUVIMED